Foundry Healthcare InvestPPEInv Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1BDX | BECTON DICKINSON & CO | Healthcare | $43.58B | 13.28% |
2TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Healthcare | $37.30B | 11.36% |
3BIIB | BIOGEN INC | Healthcare | $30.41B | 9.26% |
4MRNA | MODERNA INC | Healthcare | $24.53B | 7.47% |
5INCY | INCYTE CORP | Healthcare | $23.42B | 7.14% |
6EXEL | EXELIXIS INC | Healthcare | $14.06B | 4.28% |
7ALGN | ALIGN TECHNOLOGY INC | Healthcare | $12.66B | 3.86% |
8CRL | CHARLES RIVER LABORATORIES INTERNATIONAL INC | Healthcare | $10.81B | 3.29% |
9KYMR | KYMERA THERAPEUTICS INC | Healthcare | $9.52B | 2.90% |
10IBRX | IMMUNITYBIO INC | Healthcare | $8.04B | 2.45% |
11LNTH | LANTHEUS HOLDINGS INC | Healthcare | $7.00B | 2.13% |
12SRRK | SCHOLAR ROCK HOLDING CORP | Healthcare | $6.33B | 1.93% |
13LGND | LIGAND PHARMACEUTICALS INC | Healthcare | $6.08B | 1.85% |
14ERAS | ERASCA INC | Healthcare | $5.96B | 1.82% |
15TFX | TELEFLEX INC | Healthcare | $5.96B | 1.82% |
16TXG | 10X GENOMICS INC | Healthcare | $5.55B | 1.69% |
17CRSP | CRISPR THERAPEUTICS AG | Healthcare | $4.61B | 1.40% |
18TNGX | TANGO THERAPEUTICS INC | Healthcare | $4.13B | 1.26% |
19RLAY | RELAY THERAPEUTICS INC | Healthcare | $3.81B | 1.16% |
20ADPT | ADAPTIVE BIOTECHNOLOGIES CORP | Healthcare | $3.67B | 1.12% |
21BKD | BROOKDALE SENIOR LIVING INC | Healthcare | $3.58B | 1.09% |
22NHC | NATIONAL HEALTHCARE CORP | Healthcare | $3.56B | 1.09% |
23HAE | HAEMONETICS CORP | Healthcare | $3.54B | 1.08% |
24ESTA | ESTABLISHMENT LABS HOLDINGS INC | Healthcare | $2.72B | 0.83% |
25KOD | KODIAK SCIENCES INC | Healthcare | $2.67B | 0.81% |
26QURE | UNIQURE NV | Healthcare | $2.54B | 0.77% |
27VCEL | VERICEL CORP | Healthcare | $2.38B | 0.73% |
28NKTR | NEKTAR THERAPEUTICS | Healthcare | $2.31B | 0.70% |
29AUPH | AURINIA PHARMACEUTICALS INC | Healthcare | $2.05B | 0.63% |
30MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $1.87B | 0.57% |
31BFLY | BUTTERFLY NETWORK INC | Healthcare | $1.73B | 0.53% |
32NTLA | INTELLIA THERAPEUTICS INC | Healthcare | $1.59B | 0.48% |
33INNV | INNOVAGE HOLDING CORP | Healthcare | $1.56B | 0.48% |
34MAZE | MAZE THERAPEUTICS INC | Healthcare | $1.56B | 0.47% |
35AMN | AMN HEALTHCARE SERVICES INC | Healthcare | $1.36B | 0.41% |
36NVAX | NOVAVAX INC | Healthcare | $1.35B | 0.41% |
37ABSI | ABSCI CORP | Healthcare | $1.29B | 0.39% |
38INBX | INHIBRX BIOSCIENCES INC | Healthcare | $1.28B | 0.39% |
39TNDM | TANDEM DIABETES CARE INC | Healthcare | $1.17B | 0.36% |
40SDGR | SCHRODINGER INC | Healthcare | $1.14B | 0.35% |
41WVE | WAVE LIFE SCIENCES LTD | Healthcare | $1.12B | 0.34% |
42PCRX | PACIRA BIOSCIENCES INC | Healthcare | $1.01B | 0.31% |
43BVS | BIOVENTUS INC | Healthcare | $1.01B | 0.31% |
44VOR | VOR BIOPHARMA INC | Healthcare | $980M | 0.30% |
45ANNX | ANNEXON INC | Healthcare | $950M | 0.29% |
46TBPH | THERAVANCE BIOPHARMA INC | Healthcare | $873M | 0.27% |
47ZVRA | ZEVRA THERAPEUTICS INC | Healthcare | $755M | 0.23% |
48AURA | AURA BIOSCIENCES INC | Healthcare | $723M | 0.22% |
49OMER | OMEROS CORP | Healthcare | $701M | 0.21% |
50TCMD | TACTILE SYSTEMS TECHNOLOGY INC | Healthcare | $648M | 0.20% |
51STTK | SHATTUCK LABS INC | Healthcare | $577M | 0.18% |
52WEAV | WEAVE COMMUNICATIONS INC | Healthcare | $575M | 0.18% |
53FDMT | 4D MOLECULAR THERAPEUTICS INC | Healthcare | $575M | 0.18% |
54ANGO | ANGIODYNAMICS INC | Healthcare | $558M | 0.17% |
55DNA | GINKGO BIOWORKS HOLDINGS INC | Healthcare | $517M | 0.16% |
56RGNX | REGENXBIO INC | Healthcare | $511M | 0.16% |
57NRC | NRC HEALTH | Healthcare | $491M | 0.15% |
58VMD | VIEMED HEALTHCARE INC | Healthcare | $466M | 0.14% |
59ENTA | ENANTA PHARMACEUTICALS INC | Healthcare | $400M | 0.12% |
60STRO | SUTRO BIOPHARMA INC | Healthcare | $391M | 0.12% |
61ZNTL | ZENTALIS PHARMACEUTICALS INC | Healthcare | $364M | 0.11% |
62LYEL | LYELL IMMUNOPHARMA INC | Healthcare | $311M | 0.09% |
63TKNO | ALPHA TEKNOVA INC | Healthcare | $291M | 0.09% |
64TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $268M | 0.08% |
65QTTB | Q32 BIO INC | Healthcare | $255M | 0.08% |
66SRZN | SURROZEN INC | Healthcare | $255M | 0.08% |
67ARTV | ARTIVA BIOTHERAPEUTICS INC | Healthcare | $241M | 0.07% |
68KPTI | KARYOPHARM THERAPEUTICS INC | Healthcare | $216M | 0.07% |
69AGEN | AGENUS INC | Healthcare | $209M | 0.06% |
70IMUX | IMMUNIC INC | Healthcare | $207M | 0.06% |
71BDSX | BIODESIX INC | Healthcare | $204M | 0.06% |
72FOCL | FOCAL INC | Healthcare | $204M | 0.06% |
73DTIL | PRECISION BIOSCIENCES INC | Healthcare | $203M | 0.06% |
74AMWL | AMERICAN WELL CORP | Healthcare | $199M | 0.06% |
75DERM | JOURNEY MEDICAL CORP | Healthcare | $197M | 0.06% |
76PDEX | PRO DEX INC | Healthcare | $183M | 0.06% |
77INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $180M | 0.05% |
78INGN | INOGEN INC | Healthcare | $178M | 0.05% |
79KRRO | KORRO BIO INC | Healthcare | $177M | 0.05% |
80ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $172M | 0.05% |
81RCEL | AVITA MEDICAL INC | Healthcare | $157M | 0.05% |
82CUE | CUE BIOPHARMA INC | Healthcare | $126M | 0.04% |
83ICCC | IMMUCELL CORP | Healthcare | $101M | 0.03% |
84VRCA | VERRICA PHARMACEUTICALS INC | Healthcare | $96M | 0.03% |
85CSBR | CHAMPIONS ONCOLOGY INC | Healthcare | $85M | 0.03% |
86ACET | ADICET BIO INC | Healthcare | $76M | 0.02% |
87ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $76M | 0.02% |
88CLNN | CLENE INC | Healthcare | $76M | 0.02% |
89AGPU | AXE COMPUTE INC | Healthcare | $72M | 0.02% |
90LONA | LEONABIO INC | Healthcare | $68M | 0.02% |
91IMA | IMAGENEBIO INC | Healthcare | $61M | 0.02% |
92INKT | MINK THERAPEUTICS INC | Healthcare | $53M | 0.02% |
93XLO | XILIO THERAPEUTICS INC | Healthcare | $53M | 0.02% |
94MCRB | SERES THERAPEUTICS INC | Healthcare | $52M | 0.02% |
95EXOZ | EXOZYMES INC | Healthcare | $51M | 0.02% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $328.25B. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 89% toward Large, 54% toward Growth. +11% unclassified (17 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 95 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 95 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 51.1% | 16.0% |
| 3 yearsp.a. | 10.8% | -4.4% |
| 5 yearsp.a. | 3.5% | 2.8% |
| 10 yearsp.a. | 7.6% | -2.1% |
| Since inceptionp.a. | 7.8% | -0.5% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 20.0% | 19.6% |
| 2025 | 22.3% | -6.1% |
| 2024 | -0.7% | -17.1% |
| 2023 | -3.4% | -10.7% |
| 2022 | -11.7% | 28.6% |
| 2021 | 8.0% | -4.6% |
| 2020 | 17.5% | -9.6% |
| 2019 | 18.7% | -1.4% |
| 2018 | 2.9% | -9.8% |
| 2017 | 19.9% | 0.5% |
| 2016 | -5.0% | 1.7% |
| 2015 | 10.0% | -7.8% |
| 2014 | 16.8% | -7.6% |
| 2013 | 30.2% | -5.4% |
| 2012 | 20.2% | 2.2% |
| 2011 | 17.1% | 19.4% |
| 2010 | 13.4% | 3.1% |
| 2009 | 12.6% | -1.9% |
| 2008 | -22.7% | -10.9% |
| 2007 | 6.3% | -1.6% |
| 2006 | 10.2% | 13.6% |
| 2005 | 10.5% | -8.2% |
| 2004 | -19.0% | -17.8% |
| 2003 | 58.1% | 19.4% |
| 2002 | -25.3% | 4.3% |
| 2001 | -4.7% | 17.6% |
| 2000 | 25.7% | -20.7% |
| 1999 | 5.7% | 20.7% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare InvestPPEInv Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a InvestPPEInv signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.